While imaging of breast cancer patients still dominates HER2 imaging, O’Donoghue et al. reported the first use of [89Zr]Zr-trastuzumab in 10 esophagogastric cancer patients, where up to 80% of the known HER2-positive lesions were visualized [74,179,180]. This evidence concerns the gene ERBB2 and breast carcinoma.